The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-05. Anything still debated is marked as such rather than presented as settled.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
=== Cognitive problems ("fibro fog") === Many people with fibromyalgia experience cognitive problems often known as "fibro fog". The CDC and the American Pain Society recognize these problems as a major feature of fibromyalgia. About 75% of people with fibromyalgia report significant problems with concentration, memory, and multitasking. A 2018 meta-analysis found that the largest differences between people with fibromyalgia and healthy subjects were in inhibitory control, memory, and processing speed. A 2023 scoping review grouped effects into subjective cognitive dysfunction, perceived variability, changes in functional activities, and participation limitations. A 2017 review found that the neuropsychological mechanisms underlying brain fog may be similar to those in isolated functional cognitive disorders. One hypothesis is that chronic pain in fibromyalgia compromises attention systems, resulting in cognitive problems.
In July 2020, the European Medicines Agency (EMA) started reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to the hospital to provide an opinion on the results and in particular the potential use of dexamethasone for the treatment of adults with COVID-19. In September 2020, the EMA received an application for marketing authorization of dexamethasone for COVID-19.
== Legal and judicial figures == Richard Harison (1764), first U.S. attorney for the District of New York Peter van Schaack (1767), loyalist and attorney Abraham Van Vechten (1780s), two-time New York attorney general Anthony Bleecker (1791), lawyer and founding member of the New-York Historical Society Samuel Jones Jr. (1793), recorder of New York City; chancellor of New York; chief justice of the New York City Superior Court Augustus B. Woodward (1793), first chief justice of the Michigan Territory; one of the founders of the University of Michigan Thomas Phoenix (1795), New York County district attorney Pierre C. Van Wyck (1795), New York County district attorney; recorder of New York City William P. Van Ness (1797), judge on the United States District Court for the Southern District of New York Sampson Simson (1800), attorney, philanthropist, remembered as the "father of Mount Sinai Hospital" Alexander Hamilton Jr. (1804), son of Alexander Hamilton, attorney, soldier, and member of the New York State Assembly Hugh Maxwell (1808), New York County district attorney and Collector of the Port of New York Matthew C. Paterson (1809), New York County district attorney Ogden Hoffman (1812), former New York State attorney general, U.S. attorney for the Southern District of New York, and U.S. congressman from New York Frederic de Peyster (1819), New York attorney Theodore Sedgwick III (1829), U.S. attorney for the Southern District of New York Samuel Blatchford (1837), associate justice of the U.S.
Sources: en.wikipedia.org
The laurel leaves in the coat of arms of Kaskinen, Finland (Swedish: Kaskö), may have been meant to refer to local flowering, but its origin may also be in the name of the family Bladh (Swedish: blad; 'leaf'); two members of the family – a father and a son – acquired both town rights and the status of staple town for the village at the time.
By comparison, smaller scale civil defense programs were instituted in the United States starting in the 1950s, where schools and other public buildings had basements stocked with non-perishable food supplies, canned water, first aid, and dosimeter and Geiger counter radiation-measuring devices. Many of the locations were given "fallout shelter" designation signs. CONELRAD radio information systems were adopted, whereby the commercial radio sector (later supplemented by the National Emergency Alarm Repeaters) would broadcast on two AM radio frequencies in the event of a Civil Defense (CD) emergency. These two frequencies, 640 and 1240 kHz, were marked with small CD triangles on the tuning dial of radios of the period, as can still be seen on 1950s-vintage radios on online auction sites and museums. A few backyard fallout shelters were built by private individuals. Henry Kissinger's view on tactical nuclear war in his controversial 1957 book Nuclear Weapons and Foreign Policy was that any nuclear weapon exploded in air burst mode that was below 500 kilotons in yield and thus averting serious fallout, may be more decisive and less costly in human lives than a protracted conventional war. A list of targets made by the United States was released sometime during December 2015 by the U.S. National Archives and Records Administration. The language used to describe targets is "designated ground zeros".
=== Regional history prior to foundation of Lower Saxony === The name of Saxony derives from that of the Germanic confederation of tribes called the Saxons. Before the late medieval period, there was a single Duchy of Saxony. The term "Lower Saxony" was used after the dissolution of the stem duchy in the late 13th century to distinguish the parts of the former duchy ruled by the House of Welf from the Electorate of Saxony on one hand, and from the Duchy of Westphalia on the other.
=== Insomnia === Orexin receptor antagonists dose-dependently improve sleep parameters including latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), total sleep time (TST), and sleep quality (SQ). Orexin receptor antagonists are not currently used as first-line treatments for insomnia due to cost and concerns about possible misuse liability.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.